INDIANAPOLIS - The U.S. Food and Drug Administration has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Company’s (NYSE:LLY) Alzheimer’s treatment ...

The FDA has approved Widaplik, a polypill combining telmisartan, amlodipine, and indapamide, for the treatment of hypertension in adults, including as initial therapy. This is the first ...

Widaplik is a single tablet, triple combination therapy for hypertension that is expected to be available in the fourth quarter of 2025. The Food and Drug Administration (FDA) has approved Widaplik ™ ...

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007 ...

Learn more about the dosage of Bupropion XL and Bupropion SR, including available strengths, form, how it’s taken, and more.

Telmisartan and Hydrochlorothiazide(Micardis HCT) generic contains angiotensin II receptor blocker and diuretic, prescribed for high blood pressure.

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially serious brain swelling, according to interim results of a ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data show.

Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomized, ...

Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, ...

Aim: Hearing loss, affecting a significant portion of the global population, is prevented with peroxisome proliferator-activated receptor γ agonism. Understanding potential protective treatments is ...